



AMENDMENTS TO THE CLAIMS


The following listing of claims replaces all prior versions, and listings, of claims in this application.

1. (Original) A compound of the Formula A




wherein R' and R'' are independently selected for each position capable of substitution from the group consisting of halogen, hydroxyl, hydrogen, C₁-C₅ alkoxy, cyano (CN), and nitro (NO₂);


X is chosen from the group consisting of (C=O); O, NH, S, () and



n is an integer from 1 to 6; and pharmaceutically acceptable salts thereof.

2. (Currently amended) The compound according to claim 1 of the Formula B or the Formula C







and pharmaceutically acceptable salts thereof.


3. (Cancelled)
4. (Currently amended) The compound according to ~~claims 2 or 3~~ claim 1 wherein R' is NO₂.

5. (Currently amended) The compound according to ~~claims 1-3 or 4~~ claim 1 wherein


X is chosen from the group consisting of (, O and ().

6. (Currently amended) The compound according to ~~claims 1-4 or 5~~ claim 1 wherein n is 2, 3 or 4.

7. (Currently amended) A compound of the Formula D







wherein R''' is independently selected for each position capable of substitution ~~or~~ from the group consisting of halogen, hydroxyl, hydrogen, C₁-C₅ alkoxy, cyano (CN) and nitro (NO₂);



m is an integer from 1 to 6; and pharmaceutically acceptable salts thereof.

8. (Currently amended) The compound according to claim 7 of the Formula E, the Formula F, the Formula G or the Formula H










and pharmaceutically acceptable salts thereof.

9-11. (Cancelled).

12. (Currently amended) [[A]] The compound according to claim 2 having the Formula I, the Formula J, the Formula K, the Formula N or the Formula O









wherein [[R]] R' is selected from the group consisting of H, OH, CN and NO₂; and pharmaceutically acceptable salts thereof.

13-14. (Cancelled)



15. (Currently amended) A compound having the Formula L or the Formula M



and pharmaceutically acceptable salts thereof.

16-18. (Cancelled)


19. (Currently amended) [[A]] The compound according to claim 2 having the Formula P or the Formula Q



and pharmaceutically acceptable salts thereof.


20. (Cancelled)

21. (Currently amended) A compound having the Formula R



wherein R is chosen from the group consisting of [H,] OH, CN and NO₂ and pharmaceutically acceptable salts thereof.


22. (Original) A compound of the Formula S



wherein R is chosen from the group consisting of OH, CN and NO₂;
R' is chosen from the group consisting of H, C₁₋₆ alkyl and C₂₋₆ alkenyl;
R'' is chosen independently for each position capable of substitution from the group


consisting of H, C₁₋₆ alkyl, halogen, hydroxyl, nitro and cyano; and enantiomers and diastereomers thereof and pharmaceutically acceptable salts thereof.



23. (Original) The compound according to claim 22 wherein R' is chosen from the

group consisting of H, CH₃ and 

24. (Original) The compound according to claim 22 wherein R'' is chosen from the group consisting of H and CH₃.

25. (Currently amended) A compound of the Formula T, the Formula U or the Formula V






wherein R is selected from the group consisting of H and C₁₋₆ alkyl;

R' and R'' are each independently selected from the group consisting of H, OH, CN and NO₂ with the proviso that ~~R' = R'' = H~~, when R' is the same as R'', R' and R'' are not H, and enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

26-27. (Cancelled)


28. (Currently amended) A compound of the Formula W



wherein R is selected from the group consisting of H and ~~C₁₋₆ alkyl~~ C₁₋₆ alkyl;

R' and R'' are each independently selected from the group consisting of H, OH, CN and NO₂ with the proviso that ~~R' = R'' = H~~ when R' is the same as R'', R' and R'' are not H, and enantiomers and diastereomers thereof and pharmaceutically acceptable salts thereof.

29. (Currently amended) A compound of the Formula X




wherein R is selected from the group consisting of OH, NO₂ and CN;

R' is selected from the group consisting of H and C₁₋₃ alkyl;

R'' is selected independently for each position capable of substitution from the group consisting of halogen, hydroxyl, hydrogen, C₁₋₅ alkyl, cyano and nitro; n is [[0-6]] 0 to 6 and enantiomers and diastereomers thereof and pharmaceutically acceptable salts thereof.

30. (Currently amended) The compound according to claim 29 ~~wherein~~ having the Formula Y



and pharmaceutically acceptable salts thereof.

31. (Currently amended) The compound according to ~~claims 29 or 30~~ claim 29 wherein n is 2.

32. (Currently amended) The compound according to ~~claims 29-30 or 31~~ claim 29 wherein R' is H.

33. (Currently amended) A pharmaceutical composition comprising ~~one or more compounds~~ at least one compound according to ~~claims 1-31 or 32~~ claim 1, claim 7, claim 15, claim 21, claim 22, claim 25, claim 28 or claim 29 in a therapeutically effective amount and in combination with one or more pharmaceutically acceptable carriers or diluents.

34. (Currently amended) A method of treatment of Parkinson's Disease, ~~Tourett's~~ Tourette's syndrome, ~~Cognitive impairment-depression~~ cognitive impairment, depression, Alzheimer's disease, senile dementia, anxiety disorders, ischemic disease states, obsessive compulsive disorder, migraine, amyotrophic lateral sclerosis, epilepsy, eating disorders, premenstrual syndrome, attention deficit hyperactivity disorders, bipolar disorders, sexual

dysfunction, or psychoses, comprising administering to a patient in need of ~~said~~ such treatment a pharmaceutical composition according to claim 33.


35. (Currently amended) A method for the treatment of schizophrenia comprising administering to a patient in need of ~~said~~ such treatment a pharmaceutical composition according to claim 33.

36. (Currently amended) ~~[[A]] The method for the treatment of the positive symptoms of schizophrenia of claim 35, comprising administering to a patient in need of wherein such treatment a pharmaceutical composition according to claim 33~~ comprises treating the positive symptoms of schizophrenia.

37. (Currently amended) ~~[[A]] The method for the treatment of the negative symptoms of schizophrenia of claim 35, comprising administering to a patient in need of wherein such treatment a pharmaceutical composition according to claim 33~~ comprises treating the negative symptoms of schizophrenia.


38. (New) The compound according to claim 12 having the Formula I, wherein R' is NO₂.

39. (New) The compound according to claim 22 having the Formula S, wherein R' and R'' are both H, or wherein R' is



and R'' is H.

40. (New) The compound according to claim 22 having the formula:





and pharmaceutically acceptable salts thereof.

41. (New) The compound of claim 25 having the Formula T or the Formula U or the Formula V, wherein R' is H.

42. (New) The compound of claim 25 having the Formula T or the Formula U or the Formula V, wherein R'' is H.

43. (New) The compound of claim 28 having the Formula W, wherein R' is H or wherein R'' is H.

44. (New) The compound according to claim 2, having one of the formulas:



and pharmaceutically acceptable salts thereof.